Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00310765 · ClinicalTrials.gov registry record · Phase 4
Pregabalin for Abdominal Pain From Adhesions
A Phase 4 study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT00310765: Clinical Trial Phase 4 study, sponsored by Henry Ford Health System.
NCT00310765 is a Phase 4 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 18 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00310765, a Phase 4 study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if pregabalin demonstrates significant reduction in abdominal pain from adhesions.
Primary Outcome
Patients were randomized to pregabalin or placebo 75 mg twice a day. Patients were allowed to double the dose on day 3 if adequate pain relief was not obtained. Abdominal pain reduction was measured on a Likert scale. A Likert scale assumes the intensity of pain is linear on a continuum from no pain at level 0 to severe pain at level 10. Patients were required to complete a daily dairy recording pain using the Likert 11-point numeric scale. The primary end point was a positive change in the dail
Interventions
- DRUG Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks
- DRUG Placebo first followed by open label pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
Why NCT00310765 stopped before completion
NCT00310765 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks is the first listed.
NCT00310765 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00310765 about?
NCT00310765 is a clinical study titled "Pregabalin for Abdominal Pain From Adhesions". The purpose of this study is to evaluate if pregabalin demonstrates significant reduction in abdominal pain from adhesions.
What is the current status of trial NCT00310765?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2006-03. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00310765?
The interventions under investigation include: Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks (DRUG), Placebo first followed by open label pregabalin (DRUG).
Who is sponsoring clinical trial NCT00310765?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00310765's enrollment target sits among peer trials
18 1842nd of 2000 higher than 147 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia